EAST GRINSTEAD, West Sussex, U.K. and CLEVELAND, Nov. 18 /PRNewswire/ -- TREK Diagnostic Systems, a Magellan Biosciences business and premier provider of diagnostic systems and susceptibility products for microbiology labs, has expanded its East Grinstead, U.K., manufacturing and research and development facility to meet increasing global demand for its Sensititre® product line for susceptibility and identification testing. The expanded facility has been fully validated, and will continue to deliver the same high-quality Sensititre products, including the popular Sensititre microbroth dilution plates used in clinical and veterinary microbiology laboratories worldwide.
Just a short distance from TREK's original U.K. location, the new facility at Units 17 - 19 Birches Industrial Estate, East Grinstead, manufactures standard and custom susceptibility plates. Customers use these plates to determine what drugs and dosage levels are required to treat bacterial and yeast infections. Since the tests match the treatment course with the appropriate drugs, this helps address the growing problem of drug resistance.
More than 100 people, including East Grinstead Town Councillor Bob Mainstone, representatives from U.K. Trade and Investment and the town government, TREK employees and their families, attended a grand-opening celebration on Monday, hosted by President of Magellan Clinical Diagnostics, James Whelan. The event included a ribbon-cutting ceremony, site tour, and fun, learn-about-microbiology activities for children.
"We outgrew our previous facility thanks to increasing demand for our expanding line of susceptibility products, which provide our customers with the cost-effective, and reliable microbiology results they need to make more-informed treatment decisions," said James Whelan. "The proliferation of drug-resistant infections means that clinicians and infection-control experts are looking to us to increase report
|SOURCE TREK Diagnostic Systems|
Copyright©2009 PR Newswire.
All rights reserved